Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6ZRY4
UPID:
RBPS2_HUMAN
Alternative names:
RNA binding protein, mRNA processing factor 2
Alternative UPACC:
Q6ZRY4; A2RRG0
Background:
RNA-binding protein with multiple splicing 2 (RBPMS2) plays a pivotal role in the gastrointestinal system, specifically in smooth muscle cell differentiation and proliferation. It binds to NOG mRNA, a key inhibitor of the bone morphogenetic protein (BMP) pathway, facilitating an increase in NOG mRNA levels. This action negatively regulates the BMP signaling pathway, promoting reversible dedifferentiation and proliferation of smooth muscle cells.
Therapeutic significance:
Understanding the role of RNA-binding protein with multiple splicing 2 could open doors to potential therapeutic strategies.